Table 3 Proportion of Pfk13, Pfmdr1 and Pfcrt polymorphisms in day 0 and day of failure samples in Dihydroartemisinin−piperaquine treatment arm

Pfk13^†

 Wild type (no or mixed mutations detected)

144/145 (99.3%)

7/8 (87.5%)

Ref

27/28 (96.4%)

Ref

 522C

1/145 (0.7%)

0

1

0

1

 578S

3/145 (2.1%)

1/8 (12.5%)

0.38

2/28 (7.1%)

0.38

Pfmdr1^†

 N86

150/150 (100.0%)

8/9 (88.9%)

Ref

32/33 (97.0%)

Ref

 86 N/Y

0

0

1

0

1

 86Y

0

1/9 (11.1%)

0.18

1/33 (3.0%)

0.54

 Y184

67/150 (44.7%)

3/9 (33.3%)

Ref

13/33 (39.4%)

Ref

 184Y/F

28/150 (18.7%)

2/9 (22.2%)

1

5/33 (15.2%)

1

 184F

55/150 (36.7%)

4/9 (44.4%)

0.36

15/33 (45.5%)

1

 D1246

139/150 (92.7%)

9/9 (100%)

Ref

33/33 (100%)

Ref

 1246D/Y

6/150 (4.0%)

0

1

0

1

 1246Y

5/150 (3.3%)

0

1

0

1

 NYD

93/150 (62.0%)

5/9 (55.6%)

Ref

18/33 (54.5%)

Ref

 YFD

0

1/9 (11.1%)

0.48

1/33 (3.0%)

1

 NFD

80/150 (53.3%)

5/9 (55.6%)

1

19/33 (57.6%)

1

 NFY

7/150 (4.7%)

0

1

0

1

 NYY

7/150 (4.7%)

0

1

0

1

 YYD

0

0

1

0

1

 YFY

0

0

1

0

1

 YYY

0

0

1

0

1

Pfcrt^†

 C72

149/149 (100.0%)

9/9 (100.0%)

Ref

33/33 (100.0%)

Ref

 72S

0

0

1

0

1

 M74

148/149 (99.3%)

8/9 (88.9%)

Ref

31/33 (93.9%)

Ref

 74 M/I

0

0

1

0

1

 74I

1/149 (0.7%)

1/9 (11.1%)

0.33

2/33 (6.1%)

0.27

 N75

146/149 (98.0%)

8/9 (88.9%)

Ref

31/33 (93.9%)

Ref

 75 N/D

2/149 (1.3%)

0

1

0

1

 75E

1/149 (0.7%)

1/9 (11.1%)

0.33

2/33 (6.1%)

0.27

 K76

146/149 (99.3%)

8/9 (88.9%)

Ref

31/33 (93.9%)

Ref

 76 K/T

2/149 (1.3%)

0

1

0

1

 76T

1/149 (0.7%)

1/9 (11.1%)

0.33

2/33 (6.1%)

0.27

 CVMNK

148/149 (99.3%)

8/9 (88.9%)

Ref

31/33 (93.9%)

Ref

 CVIDT

0

0

1

0

1

 CVMDT^‡‡

2/149 (1.3%)

0

1

0

1

 CVIET

1/149 (0.7%)

1/9 (11.1%)

0.33

2/33 (6.1%)

0.27